Transcriptomic risk scores for attention deficit/hyperactivity disorder

Mol Psychiatry. 2023 Aug;28(8):3493-3502. doi: 10.1038/s41380-023-02200-1. Epub 2023 Aug 3.

Abstract

Attention deficit/hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental disorder. We performed a transcriptome-wide association study (TWAS) using the latest genome-wide association study (GWAS) meta-analysis, in 38,691 individuals with ADHD and 186,843 controls, and 14 gene-expression reference panels across multiple brain tissues and whole blood. Based on TWAS results, we selected subsets of genes and constructed transcriptomic risk scores (TRSs) for the disorder in peripheral blood mononuclear cells of individuals with ADHD and controls. We found evidence of association between ADHD and TRSs constructed using expression profiles from multiple brain areas, with individuals with ADHD carrying a higher burden of TRSs than controls. TRSs were uncorrelated with the polygenic risk score (PRS) for ADHD and, in combination with PRS, improved significantly the proportion of variance explained over the PRS-only model. These results support the complementary predictive potential of genetic and transcriptomic profiles in blood and underscore the potential utility of gene expression for risk prediction and deeper insight in molecular mechanisms underlying ADHD.

Publication types

  • Meta-Analysis

MeSH terms

  • Attention Deficit Disorder with Hyperactivity* / genetics
  • Genome-Wide Association Study
  • Humans
  • Leukocytes, Mononuclear
  • Risk Factors
  • Transcriptome* / genetics